| CAS NO: | 263251-78-1 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 263251-78-1 |
| 别名 | MIM-D3 |
| Canonical SMILES | O=C(O)CC[C@H](N1)C(N[C@@H](CCCCN)C(N[C@H](C(NCC(O)=O)=O)CCOC2=CC=C([N+]([O-])=O)C=C2C1=O)=O)=O |
| 分子式 | C24H32N6O11 |
| 分子量 | 580.54 |
| 溶解度 | Water : 5 mg/mL (8.61 mM; adjust pH to 3-4 with HCl) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF[1]. [1]. Meerovitch K, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275-85. |
m.cnreagent.com